Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proximagen losses grow on R&D drive

This article was originally published in Scrip

Executive Summary

Proximagen Neuroscience's net loss grew during the first half of 2008 as its capacity was diverted away from revenue generating service contracts and towards progressing its preclinical programmes. Pretax losses rose by £520,000 to £1.6 million following modest increases in R&D costs and lower service contract revenue. R&D costs were £1.4 million (+33%) following clinical work on its PRX5 programme in Parkinson's disease, while service contracts bought in £200,000, a decrease of £300,000. The UK company's results beat analysts' expectations at Canaccord Adams, which reiterated its buy recommendation for the firm's stock.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel